NCT06549751View on ClinicalTrials.gov

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreas Cancer
Interventions
BIOLOGICAL

MT-601

Cellular Therapy

Sponsors
All Listed Sponsors
lead

Marker Therapeutics, Inc.

INDUSTRY

NCT06549751 - MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter